Related Experiment Video
Updated: Jan 9, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network
Abigail Rai1, Mahesh Kolli2, Gaurav Pratap Singh3
1Acute Medical Unit (AMU), Impur Christian Hospital, Mokokchung, IND.
Cureus
|December 10, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show cardiorenal benefits for type 2 diabetes. Efpeglenatide demonstrated the highest efficacy in reducing major adverse cardiovascular events and renal complications in this network meta-analysis.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) significantly elevates cardiovascular and renal risks.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer potential cardioprotective and renoprotective benefits beyond glycemic control.
- Comparative efficacy among different GLP-1 RAs for these outcomes requires clarification.
Purpose of the Study:
- To evaluate and rank the effects of various GLP-1 RAs on major adverse cardiovascular events (MACE) and renal composite outcomes in patients with T2DM.
- To synthesize evidence from randomized controlled trials using a network meta-analysis (NMA) approach.
Main Methods:
- Systematic literature search across major databases (PubMed, Scopus, etc.) up to January 2024.
- Frequentist network meta-analysis (NMA) of 15 randomized controlled trials (RCTs) involving over 90,000 participants with T2DM.
- Assessment of treatment hierarchy using Surface Under the Cumulative Ranking Curve (SUCRA) values; risk of bias evaluated using Cochrane RoB2 tool.
Main Results:
- Efpeglenatide ranked highest for reducing MACE (OR: 0.74; 95% CI: 0.62-0.87; SUCRA: 81.5%) and renal outcomes (OR: 0.68; 95% CI: 0.57-0.81; SUCRA: 81.33%).
- Other GLP-1 RAs including albiglutide, semaglutide, dulaglutide, and liraglutide also showed significant benefits but with lower rankings.
- No significant inconsistency or publication bias was detected.
Conclusions:
- This NMA confirms the class-wide cardiorenal benefits of GLP-1 RAs in T2DM.
- Significant variations in efficacy exist among individual GLP-1 RAs, with efpeglenatide showing superior performance.
- Further head-to-head trials are warranted to specifically assess cardiovascular and renal endpoints.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
01:15Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
01:23Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
01:16Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656